2,022 reports of this reaction
4.6% of all OSELTAMIVIR PHOSPHATE reports
#2 most reported adverse reaction
VOMITING is the #2 most commonly reported adverse reaction for OSELTAMIVIR PHOSPHATE, manufactured by Genentech, Inc.. There are 2,022 FDA adverse event reports linking OSELTAMIVIR PHOSPHATE to VOMITING. This represents approximately 4.6% of all 43,488 adverse event reports for this drug.
Patients taking OSELTAMIVIR PHOSPHATE who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is moderately reported among OSELTAMIVIR PHOSPHATE users, representing a notable but not dominant share of adverse events.
In addition to vomiting, the following adverse reactions have been reported for OSELTAMIVIR PHOSPHATE:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 2,022 FDA reports for OSELTAMIVIR PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 4.6% of all adverse event reports for OSELTAMIVIR PHOSPHATE, making it one of the most commonly reported side effect.
If you experience vomiting while taking OSELTAMIVIR PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.